AVIEW LCS+
General Information
Product name
Company
Subspeciality
Modality
Disease targeted
Main task
Not specified
Technical Specifications
Population
Patient population age
Not specified
Input
Input format
Output
Output format
Integration
Deployment
Trigger for analysis
Processing time
Regulatory Information
Pathway:
MDR
Class:
Class IIb
Pathway:
510(k) cleared
Class:
Class II
Other certifications
Not specified
Market Presence
On market since
AI Platforms
Resellers
Countries present
Paying clinical customers
Not specified
Research/test users
Pricing Information
Pricing model
Based on
Evidence & Research
Peer-Reviewed Papers
View
Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction
View
Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: impact on negative-misclassifications and clinical referral rate
View
Artificial intelligence system for identification of overlooked lung metastasis in abdominopelvic computed tomography scans of patients with malignancy
View
Absolute ground truth-based validation of computer-aided nodule detection and volumetry in low-dose CT imaging
View
Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification
View
Variability in interpretation of low-dose chest CT using computerized assessment in a nationwide lung cancer screening program: comparison of prospective reading at individual institutions and retrospective central reading
View
Implementation of the cloud-based computerized interpretation system in a nationwide lung cancer screening with low-dose CT: comparison with the conventional reading system
Source: vendor | First published: May 2, 2024 | Last updated: Jul 14, 2025